Role of Targeted Therapy in Advanced Melanoma Treatment

2024 ASCO® Annual Meeting Insights Hub
A

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in Stage III BRAF-Mutated Melanoma"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Axel Hauschild
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Axel Hauschild
528 views
June 11, 2024
Comments 0
Login to view comments. Click here to Login
12:31

Systemic Treatment Approaches for High-Risk Melanoma

Gabriela Cinat

181 views
07:23

Long-Term Side Effects Associated With IO Treatment vs. TT in Adjuva…

Mees Egeler

326 views
14:23

Advantages & Disadvantages of Adjuvant IO vs. Targeted Treatment for…

Alexander van Akkooi

398 views
46:28

2024 Melanoma Update: Insights Into Sentinel Node Evaluation

Scripps Health

M. Ross

128 views
35:23

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

796 views
22:58

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

Tarek Haykal

730 views
25:44

Melanoma in the Molecular Age - Part 1: New Tools for Diagnosis, Pro…

Scripps Health

G. Hosler

421 views
10:01

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

AAD 2024

V. Sondak

642 views
24:40

Pathology of Melanoma

Scripps Health

B. Kelley

372 views
24:27

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuva…

2024 ASCO® Annual Meeting Insights Hub

Z. Eroglu

327 views
11:05

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and R…

2024 ASCO® Annual Meeting Insights Hub

D. Johnson

486 views
14:42

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

Jeff Yorio

547 views
13:55

Utilization of COMBI-APlus Data in Clinical Practice: Adapted Pyrexi…

Northwestern Medicine Oncology and Hematology

S. Chandra

926 views